Thank you, Monica.
So, just to provide a quick comment on the business by region. So if we look first at the Americas, this is an all-time record high quarter driven, as I said earlier, by large instrument sales, tender wins, and instrument refreshes, and sales increased to 105 million SEK, up from 66 million SEK last year.
And really, this is a reflection of our strong partnership in the US. Our sales here are really being driven by robust demand in the large and medium-sized laboratory segments, but it is also boosted by strong order books in Canada and Latin America, and this reflects excellent marketing and commercial activities that have been carried out in the run-up to the second quarter.
This year in EMEA, sales amounted to 75 million SEK, which is slightly down compared to last year. Here we see the full impact of the now concluded inventory adjustment from our main distribution partner, and we are confident that the inventory adjustment has now been fully executed. The Bone Marrow Aspirate (BMA) Application launch that I referred to earlier has generated initial sales and a lot of positive customer interest, with commercial activities supporting customer evaluations at numerous sites. These activities have remained high throughout the quarter, supported by our presence at key industry events. And it should be noted that instrument sales in EMEA are above quarter one and above the same quarter last year. For APAC, sales amounted to 19 million SEK, significantly below quarter 2, 2025. Now, on the face of it, this looks extremely disappointing. However, there are underlying positives here. We see the double impact from China, where market conditions remain challenging for current trading. But we also faced a tough comparison quarter for Q2 2025. This included significant instrument module shipments to enable us to locally produce in China, which in the long term will make us more competitive. But that quarter last year was particularly tough to compare against. If we look across the APAC region, reagent sales grew strongly, particularly in Japan and Australia. And this is excellent news for us because this is recurring business; sales were also boosted by a UN tender win. As I mentioned at the start. We now look at sales by product line, and instruments really drove the quarterly results, up 7% to 113 million SEK. As I said, it was an all-time high for large instrument sales, particularly in the Americas. The primary driver here is automated workflows for midsize and large laboratory networks. The order intake in EMEA is still slightly affected by the concluded inventory adjustment from our main partner there. And there's a steady performance in APAC with sustained traction in key markets outside of China, as I mentioned. If we look at the reagents, sales increased by 11% to 42 million SEK in the quarter, and reagent sales were in line with the same quarter last year, despite temporary delays on shipments from our production site due to the recent heat wave in France. Due to excess temperatures, we had to requalify materials from the warehouse, and this led to some delayed orders which, had that not happened, would have posted higher growth in APAC. There was strong growth across all subregions, particularly in Japan and Australia.
And then finally, if we look at software and other. The sales amounted to 46 million SEK in the quarter. It should be noted that the software sales are not completely synchronized with the instrument. Obviously we sell the instruments, but there is typically a lag or a delay, where software is then consumed once the instrument is actually installed at the customer site. Quarterly fluctuations in software sales have impacted the performance overall here. And then the other segment consists mainly of spare parts, consumables and currency effects. So if we move to slide six, just to summarize the overall picture for the quarter. Key takeaways. This quarter we delivered an increase in net sales of 4.5% to 201 million SEK. Sales increased organically by around 6% with a 1.1% headwind on FX. EBITDA delivered a result of 55 million SEK, which corresponds to a 27% EBITDA margin. And this is in line with typical returns, given the costs associated with the CEO transition. The commercial launch of the Bone Marrow Aspirate (BMA) Application marks an important milestone as we expand into specialized microscopy. We continue to progress the FDA registration process, and the aim is to obtain 510(k) market clearance in the US before year-end. From an innovation perspective, FPM technology, as I mentioned, has progressed significantly through our internal development phases. FPM will form the foundation of our next-generation hematology analyzers. This progress strengthens our confidence in FPM as a platform technology for future innovation beyond hematology in adjacent markets such as pathology and cytology.
These are excellent markets to be able to penetrate.
The results that we are seeing reinforce our confidence in the market opportunities we face, and they demonstrate progress in translating our investments in innovation into commercial results. As I step into the role of CEO, I'm committed to building on this momentum by combining our strong innovation portfolio with more focused commercial execution.
And with that, I'd now like to open up to questions. I will be ably assisted by Monica today, so if there are any questions I can answer, I'm happy to do so. And anything that requires more information or is beyond my five-week knowledge gap, I will hand over to Monica. I am very happy to receive questions.